Oppenheimer Downgrades Marinus Pharmaceuticals, Removes Price Target On Disappointing Epilepsy Study Results

By: via Benzinga
Oppenheimer has downgraded Marinus Pharmaceuticals Inc (NASDAQ: MRNS) to Perform after the company's first Phase 3 epilepsy study for ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.